Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

myeloma cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TOPK (2) ADC Antibody (3) ADC Cytotoxin (1) AMPK (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (36) Arenavirus (1) Autophagy (6) Bacterial (2) Bcl-2 Family (3) c-Kit (1) c-Myc (2) Casein Kinase (2) Caspase (2) CD3 (4) CD38 (3) CD73 (1) CDK (3) CXCR (1) Dipeptidyl Peptidase (1) DNA Alkylator/Crosslinker (2) DNA/RNA Synthesis (1) Endogenous Metabolite (1) Epigenetic Reader Domain (4) FLT3 (1) G Protein-coupled Receptor Kinase (GRK) (2) HDAC (9) Histone Demethylase (7) Histone Methyltransferase (1) HIV (7) HIV Protease (2) IAP (1) IKK (3) Interleukin Related (4) Isotope-Labeled Compounds (2) Kinesin (2) Ligands for E3 Ligase (5) MAP3K (1) MAP4K (1) Microtubule/Tubulin (3) Molecular Glues (8) NF-κB (2) Notch (2) Nuclear Factor of activated T Cells (NFAT) (1) P2X Receptor (1) p38 MAPK (2) Parasite (2) PDI (1) Phosphatase (2) Phosphodiesterase (PDE) (2) PI3K (1) Potassium Channel (1) PROTACs (4) Proteasome (3) Reactive Oxygen Species (1) SARS-CoV (1) SOD (1) STAT (1) Thyroid Hormone Receptor (1) TNF Receptor (4)
By Research Areas:	Cancer (108) Endocrinology (1) Infection (9) Inflammation/Immunology (12) Neurological Disease (1)

By Targets:

TOPK (2)

ADC Antibody (3)

ADC Cytotoxin (1)

AMPK (1)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (36)

Arenavirus (1)

Autophagy (6)

Bacterial (2)

Bcl-2 Family (3)

c-Kit (1)

c-Myc (2)

Casein Kinase (2)

Caspase (2)

CD3 (4)

CD38 (3)

CD73 (1)

CDK (3)

CXCR (1)

Dipeptidyl Peptidase (1)

DNA Alkylator/Crosslinker (2)

DNA/RNA Synthesis (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (4)

FLT3 (1)

G Protein-coupled Receptor Kinase (GRK) (2)

HDAC (9)

Histone Demethylase (7)

Histone Methyltransferase (1)

HIV (7)

HIV Protease (2)

IAP (1)

IKK (3)

Interleukin Related (4)

Isotope-Labeled Compounds (2)

Kinesin (2)

Ligands for E3 Ligase (5)

MAP3K (1)

MAP4K (1)

Microtubule/Tubulin (3)

Molecular Glues (8)

NF-κB (2)

Notch (2)

Nuclear Factor of activated T Cells (NFAT) (1)

P2X Receptor (1)

p38 MAPK (2)

Parasite (2)

PDI (1)

Phosphatase (2)

Phosphodiesterase (PDE) (2)

PI3K (1)

Potassium Channel (1)

PROTACs (4)

Proteasome (3)

Reactive Oxygen Species (1)

SARS-CoV (1)

SOD (1)

STAT (1)

Thyroid Hormone Receptor (1)

TNF Receptor (4)

By Research Areas:

Cancer (108)

Endocrinology (1)

Infection (9)

Inflammation/Immunology (12)

Neurological Disease (1)

107

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99392

Teclistamab	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

HY-105019A

Melflufen hydrochloride 1 Publications Verification Melphalan flufenamide hydrochloride	DNA Alkylator/Crosslinker Apoptosis	Cancer
Melflufen (Melphalan flufenamide) hydrochloride, a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen hydrochloride shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen hydrochloride induces irreversible DNA damage and cytotoxicity in MM cells .

HY-157216

HDAC1 Degrader-1	HDAC	Cancer
HDAC1 Degrader-1 (compound 1a) is an HDAC1 degrader with anticancer activity. HDAC1 Degrader-1 significantly reduces HDAC1 levels in MM.1S multiple myeloma cells .

HY-105019

Melflufen Melphalan flufenamide	DNA Alkylator/Crosslinker Apoptosis	Cancer
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells .

HY-119594

Melarsoprol	Parasite	Infection
Melarsoprol, a melaminophenylarsine-type trivalent organic arsenical, is an important drug for African trypanosomiasis. Melarsoprol is also active against leukemia cell lines and plasma cells from myeloma patients. Melarsoprol increases the biliary output of GSH in rats .

HY-P1846

Jagged-1 (188-204)	Notch	Cancer
Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells .

HY-P1126

Dolastatin 15 DLS 15	Microtubule/Tubulin ADC Cytotoxin Apoptosis	Cancer
Dolastatin 15 (DLS 15), a depsipeptide derived from Dolabella auricularia, is a potent antimitotic agent structurally related to the antitubulin agent Dolastatin 10. Dolastatin 15 induces cell cycle arrest and apoptosis in multiple myeloma cells. Dolastatin 15 can be used as an ADC cytotoxin .

HY-P1846A

Jagged-1 (188-204) (TFA) 5 Publications Verification	Notch	Cancer
Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells .

HY-N10259

Norfunalenone	Bacterial	Infection Cancer
Norfunalenone exhibits weak cytotoxic activity in mouse myeloma NS-1 cell line (ATCC TIB-18) with an IC₅₀ of 70 μM. Norfunalenone also exhibits weak antibacterial activity against B. subtilis (MIC=100 μg/mL; IC₅₀=265 μM) .

HY-145322

TMX-4116	Casein Kinase Molecular Glues	Cancer
TMX-4116 is a casein kinase 1α (CK1α) degrader. TMX-4116 shows the degradation preference for CK1α with DC₅₀s less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4116 can be used for the research of multiple myeloma .

HY-P9915

Daratumumab 1 Publications Verification Anti-Human CD38, Human Antibody	CD38 ADC Antibody	Inflammation/Immunology Cancer
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .

HY-10224A

Panobinostat lactate LBH589 lactate; NVP-LBH589 lactate	HDAC HIV Autophagy Apoptosis	Infection Cancer
Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma .

HY-15519

LBW242	IAP FLT3	Cancer
LBW242, a 3-mer and Smac mimetic, is a potent and orally active proapoptotic IAP inhibitor. LBW242 shows effects on mutant FLT3-expressing cells. LBW242 has activity against multiple myeloma, and potentiates TRAIL- and anticancer agent-mediated cell death of ovarian cancer cells .

HY-18712

BG45 2 Publications Verification	HDAC Apoptosis Caspase	Cancer
BG45 is a potent HDAC3 inhibitor with IC₅₀ values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis .

HY-134582

dCBP-1 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression .

HY-149832

Anticancer agent 114	Proteasome	Cancer
Anticancer agent 114 is a potent and orally active dipeptide boronic acid ester proteasome inhibitor with an IC₅₀ value of 2.2 nM. Anticancer agent 114 has antiproliferative activity against the RPMI-8226 cells. Anticancer agent 114 can be used in research of multiple myeloma .

HY-144763

XPO1-IN-1	Apoptosis	Cancer
XPO1-IN-1 (compound D4) is an orally active and potent XPO1 inhibitor, with an IC₅₀ of 24 nM in MM.1S cell. XPO1-IN-1 can efficiently induce cell apoptosis and cell cycle arrest. XPO1-IN-1 displays favorable metabolic stability and pharmacokinetic properties. XPO1-IN-1 can be used for multiple myeloma (MM) research .

HY-P99287

Elsilimomab B-E8; Anti-IL-6 MAB B-E8; Anti-Human IL6 Recombinant Antibody	Interleukin Related	Inflammation/Immunology Cancer
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a K_D of 22 pM and an IC₅₀ of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .

HY-145667

Biotinylated-JQ1 Biotin-JQ1	Epigenetic Reader Domain	Cancer
Biotinylated-JQ1 (Biotin-JQ1) is a biotinylated derivative of JQ1 with high affinity for the bromodomain of BRD4. Biotinylated-JQ1 inhibits MM1.S multiple myeloma cells proliferation with the EC₅₀ of 0.4 μM .

HY-122467

Kumbicin C	Bacterial	Infection Cancer
Kumbicin C is a bis-indolyl benzenoid compound from an Australian soil fungus, Aspergillus kumbius. Kumbicin C inhibits the growth of mouse myeloma cells and the Gram-positive bacterium Bacillus subtilis .

HY-P99814

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-*B cell* maturation antigens (BCMA*). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma* (MM) .

HY-145321

TMX-4100	Phosphodiesterase (PDE) Molecular Glues	Cancer
TMX-4100 is a selective phosphodiesterase 6D (PDE6D) degrader. TMX-4100 shows a high degradation preference for PDE6D with the DC₅₀ values less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4100 can be used for the research of multiple myeloma .

HY-115445

LCS-1	Apoptosis SOD	Cancer
LCS-1 is a superoxide dismutase 1 (SOD1) inhibitor. LCS-1 inhibits SOD1 activity with an IC₅₀ value of 1.07 μM. LCS-1 induces the early- and late-stage apoptosis of multiple myeloma (MM.1S) cells .

HY-15473A

MLN120B dihydrochloride 20+ Cited Publications ML120B dihydrochloride	IKK	Inflammation/Immunology Cancer
MLN120B dihydrochloride (ML120B dihydrochloride) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC₅₀ of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis .

HY-117987

CPS-11 N-(Hydroxymethyl)thalidomide	Nuclear Factor of activated T Cells (NFAT) NF-κB Reactive Oxygen Species	Cancer
CPS-11 (N-(Hydroxymethyl)thalidomide) a Thalidomide (HY-14658) analogue, is a potent anti-cancer agent. CPS-11 inhibits NF-κB, activates NFAT, and repress cytokine expression through elevated ROS. CPS-11 exhibits a wider activity spectrum and higher potency against MM (multiple myeloma) cell lines .

HY-131958

D942

AMPK Cancer

D942 is a cell penetrant AMPK activator and partially inhibits the mitochondrial complex I. In multiple myeloma cells, D942 inhibits cell growth .

D942	AMPK	Cancer
D942 is a cell penetrant AMPK activator and partially inhibits the mitochondrial complex I. In multiple myeloma cells, D942 inhibits cell growth .

HY-130603

DCZ0415 2 Publications Verification	NF-κB Apoptosis	Cancer
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients .

HY-122657

AI-10-104

Others Cancer

AI-10-104 is an inhibitor for runt-related transcription factor (RUNX), which enhances the cytotoxicity in myeloma cells .

AI-10-104	Others	Cancer
AI-10-104 is an inhibitor for runt-related transcription factor (RUNX), which enhances the cytotoxicity in myeloma cells .

HY-118266

BTdCPU 1 Publications Verification	Phosphatase Apoptosis	Cancer
BTdCPU is a potent heme regulated inhibitor kinase (HRI) activator that promotes eIF2α phosphorylation and induces apoptosis in Dexamethasone (HY-14648) (Dex)-resistant cancer cells. BTdCPU can be used in the study of cancers such as multiple myeloma and Dex-resistant multiple myeloma .

HY-116304

1G244 3 Publications Verification	Dipeptidyl Peptidase Apoptosis	Cancer
1G244 is a potent DPP8/9 inhibitor with IC₅₀s of 12 nM and 84 nM, respectively. 1G244 does not inhibit DPPIV and DPPII. 1G244 induces apoptosis in multiple myeloma cells and has anti-myeloma effects .

HY-100430

CCF642	Apoptosis PDI	Cancer
CCF642 is a potent protein disulfide isomerases (PDI) inhibitor with an IC₅₀ of 2.9 μM. CCF642 causes acute endoplasmic reticulum (ER) stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release. CCF642 has broad anti-multiple myeloma activity .

HY-P99536

Tagraxofusp SL-401	Interleukin Related	Cancer
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .

HY-142817

GRK6-IN-2	G Protein-coupled Receptor Kinase (GRK)	Cancer
GRK6-IN-2 (compound 10a) is a potent inhibitor of G protein-coupled receptor kinase 6 (GRK6) with an IC₅₀ of 120 nM. GRK6 is a critical kinase required for the survival of multiple myeloma (MM) cells. GRK6-IN-2 has the potential for the research of multiple myeloma .

HY-142812

GRK6-IN-1	G Protein-coupled Receptor Kinase (GRK)	Cancer
GRK6-IN-1 (compound 18) is a potent inhibitor of G protein-coupled receptor kinase 6 (GRK6) with an IC₅₀ of 120 nM. GRK6 is a critical kinase required for the survival of multiple myeloma (MM) cells. GRK6-IN-1 has the potential for the research of multiple myeloma .

HY-149513

EP12	c-Myc Apoptosis	Cancer
EP12 is a c-Myc inhibitor. EP12 is a c-Myc G4 stabilizer. EP12 induces apoptosis and DNA damage in multiple myeloma cells. EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway. EP12 inhibits multiple myeloma growth .

HY-10224S

Panobinostat-d4 LBH589-d₄; NVP-LBH589-d₄	HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride LBH589-d₄ hydrochloride; NVP-LBH589-d₄ hydrochloride	Isotope-Labeled Compounds HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-163334

GGDPS-IN-1	Others	Cancer
GGDPS-IN-1 (Compound 37) is a geranylgeranyl diphosphate synthase (GGDPS) inhibitor with an IC₅₀ of 49.4 nM. GGDPS-IN-1 disrupts protein geranylgeranylation in myeloma cells .

HY-P99798

Pacanalotamab AMG 420; BI-836909	CD3	Cancer
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3ɛ. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .

HY-160696

ORIC-533	CD73	Cancer
ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment .

HY-P3239

Belantamab mafodotin GSK2857916; Belantamab mafodotin-blm	Antibody-Drug Conjugates (ADCs)	Cancer
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity .

HY-138691

JQKD82 JADA82; PCK82	Histone Demethylase	Cancer
JQKD82 (JADA82) is a cell-permeable and selective KDM5 inhibitor. JQKD82 increases H3K4me3 and can be used for the research of multiple myeloma .

HY-138691A

JQKD82 trihydrochloride JADA82 trihydrochloride; PCK82 trihydrochloride	Histone Demethylase	Cancer
JQKD82 (JADA82) trihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 trihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma .

HY-138691B

JQKD82 dihydrochloride JADA82 dihydrochloride; PCK82 dihydrochloride	Histone Demethylase	Cancer
JQKD82 (JADA82) dihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 dihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma .

HY-137984

Cnicin	SARS-CoV	Cancer
Cnicin is a sesquiterpene lactone. Cnicin has antiproliferative effects, and induces cell death in primary myeloma cells. Cnicin also has anti-SARS-CoV-2 activity. Cnicin inhibits viral replication of SARS CoV-2 with an IC₅₀ of 1.18 μg/mL .

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Neurological Disease Cancer
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

HY-118427

Asterriquinol D dimethyl ether	Parasite Endogenous Metabolite	Infection Cancer
Asterriquinol D dimethyl ether is a fungal metabolite, which can inhibit mouse myeloma NS-1 cell lines with an IC₅₀ of 28 μg/mL. Asterriquinol D dimethyl ether also inhibits *Tritrichomonas foetus* .

HY-P99453

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is a monoclonal, targeting to B-cell maturation antigen (BCMA) and SLAMF7/CRACC/CD319, IgG1 bispecific antibody. Azintuxizumab has the potential for the research of relapsed/refractory multiple myeloma (RRMM) .

HY-149672

ABBV-467	Bcl-2 Family	Cancer
ABBV-467 is a selective MCL-1 inhibitor (K_i: <0.01 nM). ABBV-467 induces apoptosis. ABBV-467 induces cancer cell death and inhibits tumor growth in models of hematological malignancies, such as multiple myeloma .

HY-15888

PTC-209 5+ Cited Publications	Autophagy	Cancer
PTC-209 is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment .

Cat. No.	Product Name

HY-L079

Anti-Blood Cancer Compound Library

2676 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2676 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L171

Anti-Hematopathy Compound Library

2706 Compounds compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 2706 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Cat. No.	Product Name	Target	Research Area

HY-P1846A

Jagged-1 (188-204) (TFA) 5 Publications Verification	Notch	Cancer
Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells .

HY-105019

Melflufen Melphalan flufenamide	DNA Alkylator/Crosslinker Apoptosis	Cancer
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells .

HY-P1846

Jagged-1 (188-204)	Notch	Cancer
Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells .

HY-P1126

Dolastatin 15 DLS 15	Microtubule/Tubulin ADC Cytotoxin Apoptosis	Cancer
Dolastatin 15 (DLS 15), a depsipeptide derived from Dolabella auricularia, is a potent antimitotic agent structurally related to the antitubulin agent Dolastatin 10. Dolastatin 15 induces cell cycle arrest and apoptosis in multiple myeloma cells. Dolastatin 15 can be used as an ADC cytotoxin .

HY-P1700

BCMA72-80	Peptides	Cancer
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .

HY-P5472

Tumour-associated MUC1 epitope	Peptides	Others
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)

Cat. No.	Product Name	Target	Research Area

HY-P99392

Teclistamab	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

HY-P9915

Daratumumab 1 Publications Verification Anti-Human CD38, Human Antibody	CD38 ADC Antibody	Inflammation/Immunology Cancer
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .

HY-P99287

Elsilimomab B-E8; Anti-IL-6 MAB B-E8; Anti-Human IL6 Recombinant Antibody	Interleukin Related	Inflammation/Immunology Cancer
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a K_D of 22 pM and an IC₅₀ of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .

HY-P99814

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-*B cell* maturation antigens (BCMA*). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma* (MM) .

HY-119594

Melarsoprol	Parasite	Infection
Melarsoprol, a melaminophenylarsine-type trivalent organic arsenical, is an important drug for African trypanosomiasis. Melarsoprol is also active against leukemia cell lines and plasma cells from myeloma patients. Melarsoprol increases the biliary output of GSH in rats .

HY-P99381

XmAb 5592	Inhibitory Antibodies	Cancer
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .

HY-P99536

Tagraxofusp SL-401	Interleukin Related	Cancer
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .

HY-P99798

Pacanalotamab AMG 420; BI-836909	CD3	Cancer
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3ɛ. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .

HY-P3239

Belantamab mafodotin GSK2857916; Belantamab mafodotin-blm	Antibody-Drug Conjugates (ADCs)	Cancer
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity .

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Neurological Disease Cancer
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

HY-P99453

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is a monoclonal, targeting to B-cell maturation antigen (BCMA) and SLAMF7/CRACC/CD319, IgG1 bispecific antibody. Azintuxizumab has the potential for the research of relapsed/refractory multiple myeloma (RRMM) .

HY-P99400

Samalizumab ALXN 6000	Inhibitory Antibodies	Cancer
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

HY-P9915A

Daratumumab (PBS) 1 Publications Verification Anti-Human CD38, Human Antibody (PBS)	ADC Antibody CD38	Cancer
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .

HY-P99015

Dacetuzumab	TNF Receptor	Cancer
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .

HY-P99730

Mezagitamab TAK-079	CD38	Cancer
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .

HY-P99533

Urabrelimab

SRF-231; SRF231
Interleukin Related Cancer

Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .

HY-P9976

Isatuximab 1 Publications Verification	Apoptosis	Cancer
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-137984

Cnicin	Structural Classification Natural Products Source classification Centaurea benedicta (L.) L. Plants Compositae	SARS-CoV
Cnicin is a sesquiterpene lactone. Cnicin has antiproliferative effects, and induces cell death in primary myeloma cells. Cnicin also has anti-SARS-CoV-2 activity. Cnicin inhibits viral replication of SARS CoV-2 with an IC₅₀ of 1.18 μg/mL .

HY-N10259

Norfunalenone	Infection Microorganisms Classification of Application Fields Source classification Phenols Polyphenols Disease Research Fields	Bacterial
Norfunalenone exhibits weak cytotoxic activity in mouse myeloma NS-1 cell line (ATCC TIB-18) with an IC₅₀ of 70 μM. Norfunalenone also exhibits weak antibacterial activity against B. subtilis (MIC=100 μg/mL; IC₅₀=265 μM) .

HY-122467

Kumbicin C	Infection Alkaloids Microorganisms Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	Bacterial
Kumbicin C is a bis-indolyl benzenoid compound from an Australian soil fungus, Aspergillus kumbius. Kumbicin C inhibits the growth of mouse myeloma cells and the Gram-positive bacterium Bacillus subtilis .

HY-118427

Asterriquinol D dimethyl ether	Infection Alkaloids Microorganisms Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	Parasite Endogenous Metabolite
Asterriquinol D dimethyl ether is a fungal metabolite, which can inhibit mouse myeloma NS-1 cell lines with an IC₅₀ of 28 μg/mL. Asterriquinol D dimethyl ether also inhibits *Tritrichomonas foetus* .

Cat. No.	Product Name	Chemical Structure

HY-A0003S

Lenalidomide-d5

Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

HY-10224S

Panobinostat-d4

Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride

Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks